Few challenges in medicine are more daunting, or more important, than Alzheimer’s disease. That’s exactly why we have embraced this challenge, and why we will not rest until we succeed.

Duke Health’s Collaborative to Advance Clinical Health Equity (CACHE) is a community-driven initiative that leverages the power of data science to identify and eliminate health care disparities.

The OR Black Box system records virtually everything that happens from beginning to end during surgical procedures— all in the interest of making sure every patient at Duke has the safest and most positive possible outcome.

UNC Health and Duke Health are uniting to create a new children’s health system in North Carolina, featuring the state’s first freestanding hospital dedicated to caring for kids.

Last year, Duke became the first institution in North Carolina to offer lecanemab, the first drug targeting the underlying processes of Alzheimer’s disease that has shown a clinical benefit. Duke now conducts the largest lecanemab clinic in the state, giving early-stage Alzheimer’s patients the gift of time and raising awareness about the need for more research.

Researchers at the Duke Human Vaccine Institute successfully created an HIV vaccine candidate that guides key immune cells along an evolutionary pathway to become broadly neutralizing antibodies.

Patients with ductal carcinoma in situ (DCIS) are usually treated with surgery and radiation, even though it may not develop into invasive breast cancer. Dr. Shelley Hwang recently presented a study suggesting that active monitoring could be an equally effective and less aggressive option for many women.

Joel Graybeal knows what it’s like to work at a business where people mean more than the bottom line. At Triangle Rock Clubs, where he is managing partner, employees find joy in helping clients climb their way to better health and fitness. Some of them even find their soul mates: the clubs’ colorful climbing terrains have served as backdrops for several marriage proposals.

In 2017, JaNiece and Randy Saladin were devastated to learn that their 8-month-old-son, Randall, had a brain tumor. Today, Randall is thriving thanks to support from the Duke Pediatric Neuro-oncology Program team and a breakthrough FDA-approved drug.

Colton Goodman of China Grove, North Carolina, was just 3 years old when he was referred to Duke after an MRI showed a growth behind his right eye. At Duke, he was diagnosed with rhabdomyosarcoma, a life-threatening muscle tissue cancer that is most often seen in children.